Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Insulin glargine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Toujeo is a type of long-acting insulin called 'insulin glargine'.
e Toujeo Do not use Toujeo
Legende / Legend SAP-Nr. / Plant PM code: Sprachvariante / Country code: Version: Datum / Date: DMC-Inhalt / DMC content:
961692 028 1 22.05.2026 PG04 <MAT>961692
Abmessungen / Dimensions: Schriftgröße / Font size: Zeilenabstand / Line spacing: Seite / Page:
296 × 628 mm 8,5 Pt 9,5 Pt 1/2
<MAT>961692
Package leaflet: information for the user
active substance. The switch from one insulin therapy to another requires medical prescription, medical supervision and blood glucose monitoring. Talk to your doctor for further information. How much to use The Toujeo DoubleStar pre-filled pen can provide a dose of 2 to 160 units per injection, in steps of 2 units. The pen is recommended for patient who need at least 20 units of insulin per day (see also section 2). The dose window of the DoubleStar pen shows the number of units of Toujeo to be injected and no dose re-calculation is required. Your doctor will decide:
Your blood sugar level may either rise or fall if you take:
Talk to your doctor as you may need a lower dose if:
Beta-blockers Beta-blockers like other "Sympatholytic medicines" (such as clonidine, guanethidine, reserpine – for high blood pressure) can hide or stop the signs of your blood sugar being too low (hypoglycaemia) or may make it harder to recognise warning signs.
Toujeo is a long-acting insulin. Your doctor may tell you to use it with a short-acting insulin, or with other medicines for high blood sugar. Make sure you use the right type of insulin.
Pioglitazone Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke treated with pioglitazone and insulin developed heart failure.
Toujeo Always use this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure. Toujeo and insulin glargine 100 units/ml are not interchangeable, even though they contain same
Many factors may affect your blood sugar level – learn what these are and what to do if your blood sugar level changes. This will help stop it becoming too high or too low. See 'hyperglycaemia and hypoglycaemia' at the end of this leaflet for more information. When to use Toujeo
Druckbare Farben / Printing colours
Technische Information / Technical information
Black
Kontur / Outline
Do not use Toujeo
Like all medicines, this medicine can cause side effects, although not everybody gets them. Serious side effects Tell your doctor, pharmacist or nurse straight away if you notice any of the following serious side effects
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Toujeo Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and on the label of the pen after "EXP". The expiry date refers to the last day of that month. Before first use
Hyperglycaemia and hypoglycaemia If you take insulin, you should always carry the following things with you:
Low blood sugar (hypoglycaemia) Very low blood sugar may make you pass out (unconscious), cause heart attack or brain damage and be life-threatening. Learn to recognise the signs when your blood sugar is falling – and what to do to stop it getting worse. Warning signs of low blood sugar The first signs may be in your body generally:
your pen
Before first use
STEP 1: Check your pen
STEP 2: Attach a new needle
STEP 3: Do a safety test
STEP 4: Select the dose
STEP 5: Inject your dose
STEP 6: Remove the needle
✓ Take a new pen out of the fridge at least 1 hour
✓ Always use a new sterile needle for each injection. This helps stop blocked needles, contamination and infection. ✓ Only use needles that are compatible for use with Toujeo DoubleStar
✓ Always do a safety test before each injection – this is to:
✗
✗
✓ Take care when handling needles – this is to prevent needle injury and cross-infection. ✗ Never put the inner needle cap back on.
before you inject. Cold insulin is more painful to inject.
After first use
(e.g. needles from BD, Ypsomed, Artsana or Owen Mumford) that are 8 mm long or shorter.
A Check the name and expiration date on the label of your pen.
✓
Take a new needle and peel off the protective seal. A
A
is at the 4 mark.
4 units selected Pull off the outer needle cap. Keep this for later. C
B Press the injection button all the way in.
D Pull off the inner needle cap and throw away.
C
Handling needles
Legende / Legend 961692 028 1 22.05.2026 PG04
If you find it hard to press the injection button in, do not force it as this may break your pen. See the section below for help.
Places to inject
A
Upper arms
Abmessungen / Dimensions: Schriftgröße / Font size: Zeilenabstand / Line spacing: Seite / Page:
296 × 628 mm 8 Pt 9 Pt 2/2
Thighs
Repeat this step if no insulin appears:
Druckbare Farben / Printing colours
Technische Information / Technical information
Cyan Magenta Yellow Black
Kontur / Outline
urn the dose selector until the dose pointer lines up with your B T dose.
How to read the dose window The dose selector adjusts in steps of 2 units. Each line in the dose window is an even number:
60 units selected
ush the needle into your skin as shown by your doctor, pharmacist or nurse. B P
C
Place your thumb on the injection button. Then press all the way in and hold.
Keep the injection button held in and when you see "0" in the dose window, slowly D count to 5.
58 units selected
Units of insulin in your pen
Choose a place to inject as shown in the picture labelled "Places to inject" A
Select 4 units by turning the dose selector until the dose pointer
Pull off the pen cap. B
SAP-Nr. / Plant PM code: Sprachvariante / Country code: Version: Datum / Date:
Make sure a needle is attached and the dose is set to '0'.
Protect your pen from dust and dirt
Stomach
Keep the needle straight and screw it onto the pen until fixed. B Do not overtighten.
Check that the insulin is clear. C
Never select a dose or press the injection button without a needle attached. This may damage your pen. Toujeo DoubleStar is made to deliver the number of insulin units that your doctor prescribed. Do not perform any dose re-calculation.
A
Throwing your pen away
Handle your pen with care
After holding and slowly counting to 5, release the injection button. E Then remove the needle from your skin.
If you find it hard to press the button in:
ut the outer needle cap back on the needle, and use it to unscrew P the needle from the pen.
Throw away the used needle in a puncture resistant container, B or as told by your pharmacist or local authority.
Put the pen cap back on. C
What Toujeo contains
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder Sanofi 410 Thames Valley Park Drive Reading Berkshire RG6 1PT UK Tel: 0800 035 2525 email: [email protected] Manufacturer Sanofi-Aventis Deutschland GmbH, D-65926 Frankfurt am Main, Germany. This leaflet does not contain all the information about your medicine. If you have any questions or are not sure about anything, ask your doctor or pharmacist. This leaflet was last revised in April 2026
What Toujeo looks like and contents of the pack
which foods you should eat. With Toujeo, it may take longer to recover from low blood sugar because it is long-acting. 4. If the low blood sugar comes back again, take another 10 to 20 grams of sugar. 5. Speak to a doctor straight away if you are not able to control the low blood sugar – or if it comes back. What other people should do if you have low blood sugar
Toujeo® 300 units/ml solution for injection in a pre-filled pen (DoubleStar) INSTRUCTIONS FOR USE
Read this first
Toujeo DoubleStar contains 300 units/ml insulin glargine in a 3 ml disposable pre-filled pen
Important information
Learn to inject
✗ Never share your pen – it is only for you. ✗ Never use your pen if it is damaged or if you are not sure that it is working properly. ✓ Always perform a safety test before you use a new pen for the first time until you see insulin coming
out of the needle tip (see STEP 3). If you see insulin coming out the needle tip, the pen is ready to use. If you do not see insulin coming out before taking your dose, you could get an underdose or no insulin at all. This could cause high blood sugar ✓ To ensure the pen and needle are working, always perform the safety test until you see insulin coming out the needle tip before each injection (see STEP 3). If you do not perform the safety test before each injection, you may get too little insulin. ✓ Always carry a spare pen and spare needles in case they get lost or stop working.
Need help?
Extra items you will need:
If you have any questions about your pen or about diabetes, ask your doctor, pharmacist or nurse or call the Sanofi number on the front of this leaflet.
Get to know your pen Cartridge holder
Plunger*
Dose window
Dose pointer
Dose selector Pen cap
Rubber seal
Insulin scale
Insulin name
Injection button
How to care for your pen
Use by
Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen comes as injection containing 300iu. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen is insulin glargine.
Medicines with the same active substance, strength and form include: Toujeo 300 units/ml SoloStar, solution for injection in a pre-filled pen. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.
Posology
Toujeo is a basal insulin for once‑daily administration at any time of the day, preferably at the same time every day.
The dose regimen (dose and timing) should be adjusted according to individual response.
In type 1 diabetes mellitus, Toujeo must be combined with short-/rapid‑acting insulin to cover mealtime insulin requirements.
In patients with type 2 diabetes mellitus, Toujeo can also be given together with other anti‑hyperglycaemic medicinal products.
The potency of this medicinal product is stated in units. These units are exclusive to Toujeo and are not the same as IU or the units used to express the potency of other insulin analogues (see section 5.1).
Flexibility in dosing time
When needed, patients can administer Toujeo up to 3 hours before or after their usual time of administration (see section 5.1).
Patients who forget a dose, should be advised to check their blood sugar and then resume their usual once‑daily dosing schedule. Patients should be informed not to inject a double dose to make up for a forgotten dose.
Initiation
Patients with type 1 diabetes mellitus
Toujeo is to be used once‑daily with meal‑time insulin and requires individual dose adjustments.
Patients with type 2 diabetes mellitus
The recommended daily starting dose is 0.2 units/kg followed by individual dose adjustments.
Switch between insulin glargine 100 units/ml and Toujeo
Insulin glargine 100 units/ml and Toujeo are not bioequivalent and are not directly interchangeable.
- When switching from insulin glargine 100 units/ml to Toujeo, this can be done on a unit‑to‑unit basis, but a higher Toujeo dose (approximately 10-18%) may be needed to achieve target ranges for plasma glucose levels.
- When switching from Toujeo to insulin glargine 100 units/ml, the dose should be reduced (approximately by 20%) to reduce the risk of hypoglycaemia.
Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter.
Switch from other basal insulins to Toujeo
When switching from a treatment regimen with an intermediate or long‑acting insulin to a regimen with Toujeo, a change of the dose of the basal insulin may be required and the concomitant anti‑hyperglycaemic treatment may need to be adjusted (dose and timing of additional regular insulins or fast‑acting insulin analogues or the dose of non‑insulin anti‑hyperglycaemic medicinal products).
- Switching from once‑daily basal insulins to once‑daily Toujeo can be done unit‑to‑unit based on the previous basal insulin dose.
- Switching from twice‑daily basal insulins to once‑daily Toujeo, the recommended initial Toujeo dose is 80% of the total daily dose of basal insulin that is being discontinued.
Patients with high insulin doses because of antibodies to human insulin may experience an improved insulin response with Toujeo.
Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter.
With improved metabolic control and resulting increase in insulin sensitivity a further adjustment in dose regimen may become necessary. Dose adjustment may also be required, for example, if the patient's weight or life‑style changes, if there is a change in the timing of insulin dose or if other circumstances arise that increase susceptibility to hypo‑or hyperglycaemia (see section 4.4).
Switch from Toujeo to other basal insulins
Medical supervision with close metabolic monitoring is recommended during the switch and in the initial weeks thereafter.
Please refer to the prescribing information of the medicinal product to which the patient is switching.
Special populations
Toujeo can be used in elderly people, renal and hepatic impaired patients, and children and adolescents from the age of 6 years.
Elderly population (≥65 years old)
In the elderly, progressive deterioration of renal function may lead to a steady decrease in insulin requirements (see section 4.8 and 5.1).
Renal impairment
In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism (see section 4.8).
Hepatic impairment
In patients with hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Paediatric population
Toujeo can be used in adolescents and children from the age of 6 years based on the same principles as for adult patients (see sections 5.1 and 5.2). When switching basal insulin to Toujeo, dose reduction of basal and bolus insulin needs to be considered on an individual basis, in order to mimimize the risk of hypoglycaemia (see section 4.4).
The safety and efficacy of Toujeo in children below 6 years of age have not been established. No data are available.
Method of administration
Toujeo is for subcutaneous use only.
Toujeo is administered subcutaneously by injection in the abdominal wall, the deltoid or the thigh.
Injection sites must be rotated within a given injection area from one injection to the next in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see section 4.4 and 4.8).
Toujeo must not be administered intravenously. The prolonged duration of action of Toujeo is dependent on its injection into subcutaneous tissue. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycaemia.
Toujeo must not be used in insulin infusion pumps.
Toujeo is available in two pre-filled pens. The dose window shows the number of units of Toujeo to be injected. The Toujeo SoloStar and Toujeo DoubleStar pre-filled pens have been specifically designed for Toujeo and no dose re-calculation is required for either pen.
Before using Toujeo SoloStar pre-filled pen or Toujeo DoubleStar pre-filled pen, the instructions for use included in the package leaflet must be read carefully (see section 6.6).
With Toujeo DoubleStar pre-filled pen a dose of 2-160 units per single injection, in steps of 2 units, can be injected.
When changing from Toujeo SoloStar to Toujeo DoubleStar, if the patient's previous dose was an odd number (e.g. 23 units) then the dose must be increased or decreased by 1 unit (e.g. 24 or 22 units).
Toujeo DoubleStar prefilled pen is recommended for patients requiring at least 20 units per day. (see section 6.6).
Toujeo must not be drawn from the cartridge of the Toujeo SoloStar pre-filled pen or Toujeo DoubleStar pre-filled pen into a syringe or severe overdose can result (see section 4.4, 4.9 and 6.6).
A new sterile needle must be attached before each injection. Re-use of needles increases the risk of blocked needles which may cause underdosing or overdosing (see section 4.4 and 6.6).
To prevent possible transmission of disease, insulin pens should never be used for more than one person, even when the needle is changed (see section 6.6).
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Toujeo is not the insulin of choice for the treatment of diabetic ketoacidosis. Instead, regular insulin administered intravenously is recommended in such cases.
In case of insufficient glucose control or a tendency to hyper‑ or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site, and dose adjustment of antidiabetic medications may be considered.
Hypoglycaemia
The time of occurrence of hypoglycaemia depends on the action profile of the insulins used and may, therefore, change when the treatment regimen is changed.
Particular caution should be exercised, and intensified blood glucose monitoring is advisable in patients in whom hypoglycaemic episodes might be of particular clinical relevance, such as in patients with significant stenosis of the coronary arteries or of the blood vessels supplying the brain (risk of cardiac or cerebral complications of hypoglycaemia) as well as in patients with proliferative retinopathy, particularly if not treated with photocoagulation (risk of transient amaurosis following hypoglycaemia).
Patients should be aware of circumstances where warning symptoms of hypoglycaemia are diminished. The warning symptoms of hypoglycaemia may be changed, be less pronounced or be absent in certain risk groups. These include patients:
- in whom glycaemic control is markedly improved,
- in whom hypoglycaemia develops gradually,
- who are elderly,
- after transfer from animal insulin to human insulin,
- in whom an autonomic neuropathy is present,
- with a long history of diabetes,
- suffering from a psychiatric illness,
- receiving concurrent treatment with certain other medicinal products (see section 4.5).
Such situations may result in severe hypoglycaemia (and possibly loss of consciousness) prior to the patient's awareness of hypoglycaemia.
The prolonged effect of insulin glargine may delay recovery from hypoglycaemia.
If normal or decreased values for glycated haemoglobin are noted, the possibility of recurrent, unrecognised (especially nocturnal) episodes of hypoglycaemia must be considered.
Adherence of the patient to the dose and dietary regimen, correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia. Factors increasing the susceptibility to hypoglycaemia require particularly close monitoring and may necessitate dose adjustment. These factors include:
- change in the injection area,
- improved insulin sensitivity (e.g., by removal of stress factors),
- unaccustomed, increased or prolonged physical activity,
- intercurrent illness (e.g. vomiting, diarrhoea),
- inadequate food intake,
- missed meals,
- alcohol consumption,
- certain uncompensated endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or adrenocortical insufficiency),
- concomitant treatment with certain other medicinal products (see section 4.5).
Switch between insulin glargine 100 units/ml and Toujeo
Since insulin glargine 100 units/ml and Toujeo are not bioequivalent and are not interchangeable, switching may result in the need for a change in dose and should only be done under strict medical supervision (see section 4.2).
Switch between other insulins and Toujeo
Switching a patient between another type or brand of insulin and Toujeo should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (regular, NPH, lente, long-acting, etc.), origin (animal, human, human insulin analogue) and/or method of manufacture may result in the need for a change in dose (see section 4.2).
Intercurrent illness
Intercurrent illness requires intensified metabolic monitoring. In many cases urine tests for ketones are indicated, and often it is necessary to adjust the insulin dose. The insulin requirement is often increased. Patients with type 1 diabetes must continue to consume at least a small amount of carbohydrates on a regular basis, even if they are able to eat only little or no food, or are vomiting etc. and they must never omit insulin entirely.
Insulin antibodies
Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper‑or hypoglycaemia.
Combination of Toujeo with pioglitazone
Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and Toujeo is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.
Medication errors prevention
Medication errors have been reported in which other insulins, particularly rapid‑acting insulins, have been accidentally administered instead of long‑acting insulins. Insulin label must always be checked before each injection to avoid medication errors between Toujeo and other insulins (see section 6.6).
To avoid dosing errors and potential overdose, the patients must be instructed to never use a syringe to remove Toujeo (insulin glargine 300 units/ml) from the Toujeo SoloStar pre‑filled pen or Toujeo DoubleStar pre-filled pen (see section 4.9 and 6.6).
A new sterile needle must be attached before each injection. Patients must also be instructed to not re‑use needles. Re‑use of needles increases the risk of blocked needles which may cause underdosing or overdosing. In the event of blocked needle, the patients must follow the instructions described in Step 3 of the Instructions for Use accompanying the package leaflet (see section 6.6).
Patients must visually verify the number of selected units on the dose counter of the pen. Patients who are blind or have poor vision should be instructed to get help/assistance from another person who has good vision and is trained in using the insulin device.
See also section 4.2 under “Method of administration”.
Excipients
This medicinal product contains less than 1 mmol (23 mg) sodium per dose, i.e. it is essentially 'sodium‑free'.
A number of substances affect glucose metabolism and may require dose adjustment of insulin glargine.
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to hypoglycaemia include anti-hyperglycaemic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics.
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and olanzapine) and protease inhibitors.
Beta‑blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the blood‑glucose‑lowering effect of insulin. Pentamidine may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia.
In addition, under the influence of sympatholytic medicinal products such as beta‑blockers, clonidine, guanethidine and reserpine, the signs of adrenergic counter‑regulation may be reduced or absent.
Pregnancy
There is no clinical experience with use of Toujeo in pregnant women.
For insulin glargine no clinical data on exposed pregnancies from controlled clinical studies are available. A large amount of data on pregnant women (more than 1,000 pregnancy outcomes with a medicinal product containing insulin glargine 100 units/ml) indicate no specific adverse effects on pregnancy and no specific malformative nor foeto/neonatal toxicity of insulin glargine.
Animal data do not indicate reproductive toxicity.
The use of Toujeo may be considered during pregnancy, if clinically needed.
It is essential for patients with pre‑existing or gestational diabetes to maintain good metabolic control throughout pregnancy to prevent adverse outcomes associated with hyperglycaemia. Insulin requirements may decrease during the first trimester and generally increase during the second and third trimesters. Immediately after delivery, insulin requirements decline rapidly (increased risk of hypoglycaemia). Careful monitoring of glucose control is essential.
Breast‑feeding
It is unknown whether insulin glargine is excreted in human milk. No metabolic effects of ingested insulin glargine on the breast‑fed newborn/infant are anticipated since insulin glargine as a peptide is digested into aminoacids in the human gastrointestinal tract.
Breast‑feeding women may require adjustments in insulin dose and diet.
Fertility
Animal studies do not indicate direct harmful effects with respect to fertility.
The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or using machines).
Patients should be advised to take precautions to avoid hypoglycaemia whilst driving. This is particularly important in those who have reduced or absent awareness of the warning symptoms of hypoglycaemia or have frequent episodes of hypoglycaemia. It should be considered whether it is advisable to drive or use machines in these circumstances.
Summary of the safety profile
The following adverse reactions were observed during clinical studies conducted with Toujeo (see section 5.1) and during clinical experience with insulin glargine 100 units/ml.
Hypoglycaemia, in general the most frequent adverse reaction of insulin therapy, may occur if the insulin dose is too high in relation to the insulin requirement.
Tabulated list of adverse reactions
The following related adverse reactions from clinical investigations are listed below by system organ class and in order of decreasing incidence (very common: ≥1/10; common: ≥1/100 to <1/10; uncommon: ≥1/1,000 to <1/100; rare: ≥1/10,000 to <1/1,000; very rare: <1/10,000; not known: cannot be estimated from the available data).
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
MedDRA system organ classes
Very common
Common
Uncommon
Rare
Very rare
Not known
Immune system disorders
Allergic reactions
Metabolism and nutrition disorders
Hypoglycaemia
Nervous system disorders
Dysgeusia
Eyes disorders
Visual impairment
Retinopathy
Skin and subcutaneous tissue disorders
Lipohypertrophy
Lipoatrophy
Cutaneous amyloidosis
Musculoskeletal and connective tissue disorders
Myalgia
General disorders and administration site conditions
Injection site reactions
Oedema
Description of selected adverse reactions
Metabolism and nutrition disorders
Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage. Prolonged or severe hypoglycaemic episodes may be life‑threatening.
In many patients, the signs and symptoms of neuroglycopenia are preceded by signs of adrenergic counter-regulation. Generally, the greater and more rapid the decline in blood glucose, the more marked is the phenomenon of counter-regulation and its symptoms.
Immune system disorders
Immediate-type allergic reactions to insulin are rare. Such reactions to insulin (including insulin glargine) or the excipients may, for example, be associated with generalised skin reactions, angio‑oedema, bronchospasm, hypotension and shock, and may be life-threatening. In Toujeo clinical studies in adult patients, the incidence of allergic reactions was similar in Toujeo‑treated patients (5.3%) and insulin glargine 100 units/ml‑treated patients (4.5%).
Eyes disorders
A marked change in glycaemic control may cause temporary visual impairment, due to temporary alteration in the turgidity and refractive index of the lens.
Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy. However, intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy. In patients with proliferative retinopathy, particularly if not treated with photocoagulation, severe hypoglycaemic episodes may result in transient amaurosis.
Skin and subcutaneous tissue disorders
Lipodystrophy and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (see section 4.4).
General disorders and administration site conditions
Injection site reactions include redness, pain, itching, hives, swelling, or inflammation. Most minor reactions to insulins at the injection site usually resolve in a few days to a few weeks. In Toujeo clinical studies in adult patients, the incidence of injection site reactions was similar in Toujeo‑treated patients (2.5%) and insulin glargine 100 units/ml‑treated patients (2.8%).
Rarely, insulin may cause oedema particularly if previously poor metabolic control is improved by intensified insulin therapy.
Paediatric population
Safety and efficacy of Toujeo have been demonstrated in a study in children aged 6 to less than 18 years. The frequency, type and severity of adverse reactions in the paediatric population do not indicate differences to the experience in the general diabetes population (see section 5.1). Clinical study safety data are not available for children under 6 years.
Other special populations
Based on the results from clinical studies, the safety profile of Toujeo in elderly patients and in patients with renal impairment was similar to that of the overall population (see section 5.1).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms
Insulin overdose may lead to severe and sometimes long-term and life-threatening hypoglycaemia.
Management
Mild episodes of hypoglycaemia can usually be treated with oral carbohydrates. Adjustments in dose of the medicinal product, meal patterns, or physical activity may be needed.
More severe episodes with coma, seizure, or neurologic impairment may be treated with glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
Ask anything about Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.